4.6 Article

MicroRNAs in immune regulation-Opportunities for cancer immunotherapy

Journal

INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Volume 42, Issue 8, Pages 1256-1261

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.biocel.2010.02.002

Keywords

MicroRNA; Type-1 helper (Th1); Cancer; Cancer immunology; High-mobility group box (HMGB)1

Funding

  1. NCI NIH HHS [1P01CA132714, P01 CA101944-02, P01 CA101944, P01 CA132714-01A18081, P01 CA132714, P01 CA 101944] Funding Source: Medline
  2. NCRR NIH HHS [1U54RR023506] Funding Source: Medline
  3. NINDS NIH HHS [R01 NS055140, 1R01NS055140, 2P01 NS40923, P01 NS040923-070005, P01 NS040923, R01 NS055140-03] Funding Source: Medline

Ask authors/readers for more resources

Endogenously produced microRNAs are predicted to regulate the translation of over two-thirds all human gene transcripts. Certain microRNAs regulate expression of genes that are critically involved in both innate and adaptive immune responses. Immune cells represent a highly attractive target for microRNA gene therapy approaches, as these cells can be isolated, treated and then reintroduced into the patient. In this short review, we discuss how recent discoveries on the roles of microRNAs in immune-regulation will advance the field of cancer immunology and immunotherapy. Targets identified already in T cells include microRNAs, miR-17-92 family, miR-155, and miR-181a. In macrophages. miR-125b, miR-146, and miR-155 act as Pathogen Associated Molecular Pattern Molecule-associated microRNAs and miR-34C and miR-214 as Damage Associated Molecular Pattern Molecules-associated miRs. We have also demonstrated that the ability of tumors to serve as targets for cytolytic effectors is regulated by miR-222 and miR-339. (C) 2010 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available